Business Wire

Westlake Epoxy Unveils Cutting-Edge Composite Solutions at JEC World 2025

Share

Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy plans to launch several new products at the JEC World Show 2025, March 4 to 6, in Paris. We will be showcasing at booth 6-P114 our latest innovations designed to enhance efficiency, safety, and performance.

Throughout the years, Westlake Epoxy has cultivated a broad network, bringing together equipment manufacturers, formulators, automators, and end users to create unique practical solutions for the growing composites industry. These partnerships have significantly contributed to the development of our product offerings, including EpoVIVE™, a more sustainable epoxy product portfolio that will be launched at JEC World.

Epoxy products are used in the manufacturing of critical components such as rotor blades for wind turbine generators, helicopter center longerons, and H2 tanks, marking a significant advancement in our sustainable composite solutions portfolio. Discover them at our booth and experience innovation in action, with:

  • NEW The Recyclable Rotor Blade Technology for WindTurbines – Our innovative approach to rotor blade production features a novel, recyclable technology, enabling separation of the matrix from fiber, with subsequent reuse of the matrix in composite applications.
  • Thefast, reliable and cost-efficient blade maintenance and repairs products.
  • The NEW EpoVIVE™ products with increased bio-based content, enables the aeronautical industry to significantly reduce the Product Carbon Footprint (PCF) of molded parts, regardless of the production process, including RTM, Prepreg, and others.
  • The Phenolic Fiber-Reinforced Battery Cover for the automotive application which combines high mechanical performance and continuous fiber reinforcement with a ‘snap curable’ best-in-class FST (Fire Smoke Toxicity) resin system.
  • The versatile and long-lasting hydrogen storage solutions – Our range of products is developed to embrace the longevity of vessels across various applications, maximizing storage efficiency, ensuring safety, and energy saving, all while maintaining the purity of the gases.
  • The Next Generation Gravel Bike Technology – Experience the advantages of the lightweight technology for improved performance and durability.

“Our goal is to push the boundaries of material performance while ensuring efficiency, safety, and sustainability,” says Karl-Martin Schellerer, Senior Vice President, Performance and Essential Materials - Europe and Asia. “We’re excited to connect with industry professionals and demonstrate how our solutions can help them achieve their goals.”

To learn more about EpoVIVE™ products and Westlake Epoxy new developments, we invite you to participate in the technical presentation entitled “Innovative Solutions for sustainable Composites”, presented by Sigrid ter Heide, on Wednesday, March 05th, at 11:30-11:55, at Composite Exchange, Agora, Hall 6.

At Westlake Epoxy we aspire to continuously improve our Environmental, Sustainable and Governance journey. Westlake Epoxy is committed to reducing its carbon footprint through sustainable sourcing, products, and manufacturing processes. Together, we are enhancing your life every day!

About Westlake

Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227077090/en/

Contacts

Media contact:

Dr. Oliver Mieden, Head of Communications & Public Affairs – Europe and Asia
Westlake Germany GmbH & Co. KG, Carl-Zeiss-Ring 25, 85737 Ismaning, Germany
Phone: +49 (0)89 96103-282, E-mail: oliver.mieden@westlake.com

Mila Hierner, Global Marketing Communication Manager
Westlake Epoxy Belgium BV, Avenue Jean Monnet 1, 1348 Ottignies
Louvain-la-Neuve, Belgium
Office: +32 10 48 22 50, E-mail: mila.hierner@westlake.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting28.2.2025 16:30:00 EET | Press release

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. "We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this year's AAD Annual Meeting,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. "Incyte’s active participation in this key congress reinforces our commitment to addressing critical needs in dermatology while fostering meaningful dialogue with researchers, patients and advocates to inform the development of innovative treatments.” Key abstracts include: Late-Breaking Oral Presentation Prurigo Nodularis (PN) Efficacy and Safety of Ruxolitinib Cream in Patients With Prurig

ENHERTU ® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy28.2.2025 15:00:00 EET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and pu

Radisys Expands Small Cell Portfolio with Qualcomm Dragonwing FSM200 Platform for FR1 and FR228.2.2025 15:00:00 EET | Press release

Radisys® Corporation, a global leader of open telecom solutions, announced the availability of its award-winning Connect RAN software on the Qualcomm Dragonwing™ FSM200 Platform for both FR1 and FR2. The solution leverages baseband and advanced Radio capabilities of the Dragonwing FSM200 platform to address high performance/capacity use cases with advanced features required in various market segments, including MNOs, enterprise, Fixed Wireless Access (FWA), private 5G, Industry 4.0 and home networks. Radisys Connect RAN software on the Qualcomm Dragonwing™ FSM100 platform is already globally deployed for various use cases. Radisys' Connect RAN 5G solution offers a comprehensive feature set, fully interoperable with a wide ecosystem and robust manageability support, enabling customers to deploy small cells in multiple verticals at reduced operational and capital expenses with a quick time-to-market. Highlights Radisys demonstrated continued leadership in mmWave RAN on Dragonwing FSM100

Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO ® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations28.2.2025 14:22:00 EET | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We are thrilled by the positive CHMP opinion in support of expanding the KAFTRIO in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,” said Fosca De Iorio, M.D., Vice President, International Medical Affairs at Vertex. “If approved, thousands of additional patients across Europe will be eligible for a CFTR modulator, bringing us closer than ever to our goal of getting treatments that address the underlying cause of the disease to all people living with CF.” In the Eur

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order28.2.2025 14:00:00 EET | Press release

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and (ii) the Company’s Rights Agreement (also known as poison pill agreement) was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order. As the Company's Rights Agreement is void, all the exchange shares issued pursuant to the Rights Agreement (the “Exchange Shares”), including 27,777,341 common shares and all 14,630,813 Convertible Series B Preferred Shares of SINOVAC, held by the 2019 Rights Exchange Trust, are void and will be cancelled. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye